Identifying biologically distinct subgroups, such as patients with central adiposity, insulin resistance, or elevated inflammatory markers, may enable the development of stratified treatment approaches, improving the likelihood of clinical benefit from GLP-1 RAs and similar agents [102]. The gene discussed is GCG; the disease is Insulin resistance.